Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
A phase 1/2 trial of Purinostat in multiple myeloma, run by Chengdu Zenitar Biomedical Technology Co., Ltd, now recruiting.
Overview
Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT06484829 by Chengdu Zenitar Biomedical Technology Co., Ltd, with 144 participants planned, started 2024-03-25 and due to reach its primary completion in 2026-02-01. Interventions recorded: Purinostat Mesylate 4 mg/m2, Purinostat Mesylate 6 mg/m2 and Purinostat Mesylate 8.4 mg/m2.
Similar pages
not linked directly; found by shared links- TrialA Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors
Shares Purinostat, Chengdu Zenitar Biomedical Technology and the tag pipeline.
- TrialA Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
Shares Purinostat, Chengdu Zenitar Biomedical Technology and the tag pipeline.
- TrialStudy of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
Shares Chengdu Zenitar Biomedical Technology and the tag pipeline.
- TrialA Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma
- TrialPhase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera
Shares Chengdu Zenitar Biomedical Technology and the tag pipeline.
- TrialHuman BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialStudy of ODX (OsteoDex) in Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.